BIO to cut ties with WuXi af­ter trade group was ac­cused of act­ing as a for­eign agent

The biotech in­dus­try’s ma­jor lob­by­ing group in Wash­ing­ton will end its as­so­ci­a­tion with the Chi­nese ser­vices com­pa­ny WuXi AppTec, which has been tar­get­ed by mem­bers of Con­gress as a US na­tion­al se­cu­ri­ty risk.

In a press re­lease Wednes­day af­ter­noon, the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion said it will take steps to “sep­a­rate from WuXi-AppTec re­gard­ing mem­ber­ship” and sup­port the BIOSE­CURE Act. That leg­is­la­tion would po­ten­tial­ly ban WuXi and sev­er­al oth­er Chi­nese health­care firms from do­ing work in the US or with US com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER